Crain's New York

Midtown company tells investors esophageal pre-cancer screening should be an easier pill to swallow

A Midtown-based diagnostics company raised capital in a deal to advance its novel approach to screening for the risk factors of esophageal cancer, a highly deadly cancer for which a diagnosis is ...
Morningstar

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

Lucid's EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device, represent the first and only ...
Seeking Alpha

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

NEW YORK, April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (LUCD) (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of ...
Longview News-Journal

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy "This update is an important step ...
Business Insider

Lucid Diagnostics secures first positive insurance coverage for EsoGuard test

Lucid Diagnostics (LUCD) announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, has issued a positive coverage policy for non-invasive ...
KXAN

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

NEW YORK, July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc ...